MTEM: mtem.com Earnings per share for the last twelve months

Graphic logo of mtem.com (MTEM)

The risky niche of oncology toxin platforms creates a fierce struggle for capital, as confirmed by the annual revenue per share of Molecular Templates (MTEM). The -2.72 mark reflects the latest data, while laboratory robotization and computer modeling minimize manual labor. Meanwhile, the international humanitarian status of healthcare ensures the business remains completely independent of geopolitical risks.

MTEM Molecular Templates Corporation Earnings per share for the last twelve months (07/04/2022 - 12/28/2024)

Molecular Templates Corp (MTEM) - metric breakdowns and financial figures

- share price and expert price forecast:
Stock Quotes Molecular Templates, Inc.|MTEM - Fair Value Consensus
- market capitalization information:
Market Value Molecular Templates Inc|MTEM - Full Business Value
- shareholders' equity book value data:
Net Assets per Single Share Molecular Templates|MTEM - Company Book Value|Market Capitalization to Book Value Ratio mtem.com|MTEM - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Molecular Templates|MTEM - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Molecular Templates Corp|MTEM - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Molecular Templates, Inc.|MTEM - Long-Term Debt|Company Short-Term Debt Molecular Templates|Quick Liquidity mtem.com
- earnings and multiples data:
MTEM - Net Income|Expected Profit Molecular Templates|MTEM - Business Payback Period|Future Price to Earnings Molecular Templates Corporation|MTEM - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Molecular Templates, Inc.|MTEM - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Molecular Templates|MTEM - Earnings per share for the last twelve months|Quarterly EPS earnings growth mtem.com|MTEM - Earnings per share growth rate in current year|Earnings growth forecast for next year Molecular Templates
- sales and revenue indicators:
MTEM - Company Sales|Company Future Sales Volume mtem.com|MTEM - P/S Multiple|Price-to-Projected Revenue Ratio Molecular Templates Corp
Summary company analysis:MTEM - Molecular Templates Corporation
Flagship merchandise of Molecular Templates Inc

A comparative asset analysis requires separating market noise from actual business performance. This metric aggregates annual net income and divides it by the total number of shares to determine the owner's share of operational results. Developing innovative anti-cancer toxins requires immense expenditures, which directly impacts profitability. The GURU.Markets toolkit allows for the tracking of these changes. By analyzing net income per share over the last four quarters, an investor can identify the fundamental reversal point for Molecular Templates (MTEM).

Main competitors

GERN: Net earnings per share for the last 12 months|Earnings per share for the trailing year NBTX (Nanobiotix SA)|Bicycle Therapeutics plc (BCYC) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months CTMX (CytomX Corp)|Earnings per share for the last twelve months Perspective Therapeutics|Earnings per share for the last twelve months GNLX|Net earnings per share (EPS TTM) MOLN|Net earnings per share (EPS TTM) Oncolytics (ONCY)|Lisata Therapeutics, Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters MBRX (Moleculin)|Galera Therapeutics - Net earnings per share (EPS TTM)